Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC. (EXEL)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
29.02(c) 28.3(c) 27.53(c) 27.46(c) 27.17(c) Last
29 948 192 8 001 754 5 060 144 3 788 304 2 742 556 Volume
+17.21% -2.48% -2.72% -0.25% -1.06% Change
More quotes
Financials ($)
Sales 2017 399 M
EBIT 2017 97,1 M
Net income 2017 86,5 M
Finance 2017 234 M
Yield 2017 -
Sales 2018 582 M
EBIT 2018 204 M
Net income 2018 207 M
Finance 2018 405 M
Yield 2018 -
P/E ratio 2017 98,30
P/E ratio 2018 40,89
EV / Sales2017 19,4x
EV / Sales2018 13,0x
Capitalization 7 985 M
More Financials
Company
Exelixis, Inc. is a biopharmaceutical company.It engages in the developing and commercializing small molecule therapies for the treatment of cancer.The company brands include comertriq and cobimetinib.Its pipeline consists of cabozantinib, cobimetinib and Xl 888. Exelixis was founded by Corey S.... 
More about the company
Surperformance© ratings of Exelixis, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on EXELIXIS, INC.
10/19 EXELIXIS, INC. : Exelixis, Positive News from Celestial Study, Cabometyx Label R..
10/19 EXELIXIS : FDA grants priority review for Exelixis Cabometyx to treat advanced R..
10/18 EXELIXIS : to Release Third Quarter 2017 Financial Results on Wednesday, Novembe..
10/18 EXELIXIS, INC. : Featured Company News - Exelixis' Cabozantinib Met Primary Endp..
10/18 IPSEN : announces that phase 3 CELESTIAL trial of cabozantinib meets primary end..
10/18 EXELIXIS' : Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Ov..
10/18 EXELIXIS : Announces U.S. FDA Grants Priority Review for CABOMETYX as a Treatmen..
10/18 IPSEN : announces that phase 3 CELESTIAL trial of cabozantinib meets primary end..
10/17 HERE’S WHAT’S MOVING EXE : EXEL) Right Now
10/17 EXELIXIS : shares soar on news FDA grants priority review to its kidney cancer d..
More news
Sector news : Bio Therapeutic Drugs
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on EXELIXIS, INC. 
EXELIXIS - 2013
A downturn could form
SELL
More Strategies
Latest Tweets
10/21Exelixis liver cancer drug meets late-stage goal, shares jump
8
10/21Exelixis, Inc. $EXEL Upgraded to B- at TheStreet  
10/20Watch Us Report LIVE from the Floor of the NYSE! This weeks weekly wrap-up in.. 
10/20Watch Us Report LIVE from the Floor of the NYSE! This weeks weekly wrap-up in.. 
10/20Watch Us Report LIVE from the Floor of the NYSE! This weeks weekly wrap-up in.. 
More tweets
Qtime:97
News from SeekingAlpha
10/19 BIOTECH DEVELOPER STOCKS : What Are The Best Wealth-Builders Now?
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/18 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 18, 2017
10/17 YOUR DAILY PHARMA SCOOP : Everybody's Gilead Problem, Halozyme's Further Progres..
10/17 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 17, 2017
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | 4-Traders
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 32,3 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Executive VP, Chief Financial & Accounting Officer
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.84.17%7 985
GILEAD SCIENCES11.73%106 054
REGENERON PHARMACEUTICALS19.69%46 395
VERTEX PHARMACEUTICALS110.07%38 985
ACTELION23.81%29 840
GENMAB14.75%12 865